

Federica Perrone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9291443/publications.pdf>

Version: 2024-02-01

114
papers

6,504
citations

76326

40
h-index

66911

78
g-index

114
all docs

114
docs citations

114
times ranked

11395
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5630-5636.	1.6	605
2	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2009, 20, 84-90.	1.2	366
3	EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. <i>American Journal of Pathology</i> , 2009, 174, 661-670.	3.8	301
4	Elevated Risk for MPNST in NF1 Microdeletion Patients. <i>American Journal of Human Genetics</i> , 2003, 72, 1288-1292.	6.2	271
5	BRAF alterations are associated with complex mutational profiles in malignant melanoma. <i>Oncogene</i> , 2004, 23, 5968-5977.	5.9	189
6	Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. <i>Annals of Surgical Oncology</i> , 2013, 20, 4096-4102.	1.5	187
7	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009, 45, 574-578.	1.5	184
8	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	4.1	162
9	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 6643-6651.	7.0	159
10	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 74362-74379.	1.8	149
11	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009, 45, 986-990.	1.5	144
12	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	1.2	137
13	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	7.0	135
14	Smoothed (SMO) receptor mutations dictate resistance to Vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015, 9, 389-397.	4.6	131
15	miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. <i>Molecular Cancer Research</i> , 2012, 10, 504-515.	3.4	123
16	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. <i>British Journal of Cancer</i> , 2014, 110, 1001-1007.	6.4	118
17	Rb and TP53 Pathway Alterations in Sporadic and NF1-Related Malignant Peripheral Nerve Sheath Tumors. <i>Laboratory Investigation</i> , 2001, 81, 833-844.	3.7	117
18	TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 761-766.	1.6	104

#	ARTICLE	IF	CITATIONS
19	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-“positive salivary gland cancers. <i>Head and Neck</i> , 2016, 38, 724-731.	2.0	104
20	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	1.2	97
21	<i>TP53</i> , <i>p14</i> ^{ARF} , <i>p16</i> ^{INK4a} and <i>Kras</i> gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>International Journal of Cancer</i> , 2003, 105, 196-203.	5.1	89
22	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 963-971.	9.4	85
23	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016, 7, 4428-4441.	1.8	84
24	Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015, 75, 1205-1215.	0.9	78
25	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 12731-12747.	1.8	77
26	Frequent Mutation and Nuclear Localization of β -Catenin in Sertoli Cell Tumors of the Testis. <i>American Journal of Surgical Pathology</i> , 2014, 38, 66-71.	3.7	72
27	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. <i>Neuro-Oncology</i> , 2009, 11, 725-736.	1.2	71
28	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	2.5	70
29	p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4132-8.	7.0	69
30	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	1.2	67
31	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	2.8	66
32	Isolating p16-positive/HPV-negative Oropharyngeal Cancer. <i>American Journal of Surgical Pathology</i> , 2011, 35, 774-777.	3.7	65
33	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016, 22, 3961-3970.	7.0	65
34	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012, 77, 507-514.	2.0	64
35	Intestinal type adenocarcinoma of the ethmoid sinus in wood and leather workers: A retrospective study of 153 cases. <i>Head and Neck</i> , 2011, 33, 535-542.	2.0	61
36	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for kit and platelet-derived growth factor receptor \pm gene alterations. <i>Cancer</i> , 2005, 104, 159-169.	4.1	56

#	ARTICLE	IF	CITATIONS
37	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine-“DNA Methyltransferase”-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	1.6	52
38	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. <i>Autophagy</i> , 2012, 8, 1185-1196.	9.1	51
39	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
40	Integrative approach for prioritizing cancer genes in sporadic colon cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 953-962.	2.8	47
41	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
42	PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic β^2 -catenin and affects membrane distribution of β^2 -catenin/E-cadherin complexes in cancer cells. <i>Cellular Signalling</i> , 2008, 20, 872-883.	3.6	41
43	DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 23-37.	3.1	41
44	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1053-1059.	0.8	39
45	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013, 49, 413-419.	1.5	39
46	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. <i>Tumori</i> , 2014, 100, 115-121.	1.1	39
47	Lack of SYT-SSX Fusion Transcripts in Malignant Peripheral Nerve Sheath Tumors on RT-PCR Analysis of 34 Archival Cases. <i>Laboratory Investigation</i> , 2002, 82, 609-618.	3.7	38
48	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	1.9	38
49	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	3.3	38
50	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	4.4	36
51	Targeted Therapies: The Rare Cancer Paradigm. <i>Molecular Oncology</i> , 2010, 4, 19-37.	4.6	34
52	Phenotype-“genotype correlation: Challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006, 28, 909-915.	2.0	33
53	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014, 25, 694-699.	1.2	33
54	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007, 109, 2461-2465.	4.1	31

#	ARTICLE	IF	CITATIONS
55	Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed β -catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 31-47.	2.8	31
56	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. <i>European Journal of Cancer</i> , 2010, 46, 2837-2848.	2.8	30
57	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 112.	3.7	30
58	β -Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017, 11, 1495-1507.	4.6	28
59	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. <i>Cancer Biology and Therapy</i> , 2013, 14, 1098-1103.	3.4	27
60	<i>AKT1</i> and <i>BRAF</i> mutations in pediatric aggressive fibromatosis. <i>Cancer Medicine</i> , 2016, 5, 1204-1213.	2.8	27
61	Circulating free DNA in a screening program for early colorectal cancer detection. <i>Tumori</i> , 2014, 100, 115-21.	1.1	27
62	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014, 9, 155-162.	3.6	26
63	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	1.1	26
64	Prognostic significance of the CaMBr1 antigen on breast carcinoma: Relevance of the type of recognised glycoconjugate. <i>European Journal of Cancer</i> , 1993, 29, 2113-2117.	2.8	24
65	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1886-1893.	1.2	24
66	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 678-682.	3.4	24
67	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	3.6	23
68	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	2.5	22
69	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 718-728.	1.1	22
70	Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 139-151.	3.0	22
71	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
72	Challenging Lung Carcinoma with Coexistent ^{63}Ni /p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1500-1502.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	3.7	19
74	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported <i>EWSR1</i> – <i>FEV</i> translocation. <i>Histopathology</i> , 2014, 64, 1014-1026.	2.9	19
75	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
76	Novel intra-genic large deletions of <i>CTNNB1</i> gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 495-503.	2.8	18
77	Neuroendocrine Small Cell Carcinoma of the Cervix Associated with Endocervical Adenocarcinoma. <i>Acta Cytologica</i> , 2007, 51, 589-593.	1.3	17
78	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.7	17
79	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015, 51, 473-481.	2.8	17
80	Functional analysis and molecular modeling show a preserved wild-type activity of p53C238Y. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1467-1473.	4.1	16
81	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. <i>Oncotarget</i> , 2016, 7, 75503-75517.	1.8	16
82	Clear cell adenocarcinoma of the colon is a unique morphological variant of intestinal carcinoma: Case report with molecular analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 6575.	3.3	16
83	In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. <i>Human Pathology</i> , 2018, 74, 32-42.	2.0	15
84	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 217-227.	5.5	15
85	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	2.8	14
86	FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 342-348.	1.6	12
87	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	2.3	12
88	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019, 90, 94-101.	1.5	12
89	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 922.	3.7	12
90	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5817.	4.1	11
92	TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. <i>Oncology</i> , 2014, 86, 289-294.	1.9	10
93	Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed Patients. <i>Translational Oncology</i> , 2009, 2, 84-88.	3.7	9
94	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	1.2	9
95	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 497-503.	2.8	8
96	Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. <i>International Journal of Surgical Pathology</i> , 2014, 22, 136-148.	0.8	8
97	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 734-745.	2.7	8
98	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 435-443.	4.1	8
99	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, e226-e228.	1.2	7
100	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013, 30, 610.	2.5	7
101	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
102	BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. <i>Tumori</i> , 2014, 100, 315-20.	1.1	6
103	Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2015, 87, 204-206.	2.0	5
104	Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients. <i>Human Pathology</i> , 2016, 47, 157-158.	2.0	4
105	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017, 2017, 1-9.	1.3	4
106	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018, 104, 213-220.	1.1	4
107	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016, 58, e4-e5.	1.5	3
108	Re: Oda et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. <i>J Pathol</i> 2005;207:410-421. <i>Journal of Pathology</i> , 2006, 209, 281-281.	4.5	2

#	ARTICLE	IF	CITATIONS
109	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. Clinical and Translational Oncology, 2013, 15, 582-586.	2.4	2
110	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 451-461.	2.8	2
111	Genetic Markers in Sporadic Tumors. , 2008, , 43-84.		2
112	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2
113	TP53Mutations in Head and Neck Cancer. New England Journal of Medicine, 2008, 358, 1194-1195.	27.0	1
114	Peritoneal Mesothelioma. Updates in Surgery Series, 2015, , 243-254.	0.1	0